Lechleider Robert
Chief Medical Officer
Lechleider Robert has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Jul 27, 2026.
On the most recent filing, Lechleider Robert is listed as Chief Medical Officer at Immunome Inc. Inside the rolling window, Lechleider Robert reported no open-market purchases and 2 open-market sales totaling $2.3M in IMNM. The largest disclosed transaction in the window is a sale of 55,000 IMNM shares on Jul 2, 2026, worth $1.2M.
Companies traded
Other insiders at IMNM
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.3M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lechleider Robert made?
Lechleider Robert has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company since 2026.
Which companies does Lechleider Robert trade?
Lechleider Robert has filed SEC Form 4 disclosures for 1 company, including IMNM.
When was Lechleider Robert's most recent SEC Form 4 filing?
Lechleider Robert's most recent SEC Form 4 filing on Tracefour is dated Jul 27, 2026.
What is Lechleider Robert's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Lechleider Robert is listed as Chief Medical Officer.
What is Lechleider Robert's total buy and sell value in the current window?
Inside the rolling retention window, Lechleider Robert bought $0 and sold $2.3M based on SEC Form 4 filings.
What was Lechleider Robert's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 55,000 IMNM shares on 2026-07-02, worth $1.2M, per SEC Form 4 filings.